|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/25/20 NTN Buzztime Inc. S-4/A 207:22M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-4/A Pre-Effective Amendment to Registration Statement HTML 4.43M
- Securities for a Merger
2: EX-5.1 Opinion of Counsel re: Legality HTML 58K
3: EX-10.16(A) Material Contract HTML 72K
4: EX-10.16(B) Material Contract HTML 74K
5: EX-10.17(A) Material Contract HTML 72K
6: EX-10.17(B) Material Contract HTML 58K
7: EX-10.17(C) Material Contract HTML 74K
8: EX-10.17(D) Material Contract HTML 66K
9: EX-10.18 Material Contract HTML 74K
10: EX-10.19(A) Material Contract HTML 235K
11: EX-10.19(B) Material Contract HTML 61K
12: EX-10.19(C) Material Contract HTML 72K
13: EX-10.20 Material Contract HTML 126K
14: EX-10.21 Material Contract HTML 68K
15: EX-10.22 Material Contract HTML 71K
16: EX-10.23(A) Material Contract HTML 284K
17: EX-10.23(B) Material Contract HTML 63K
18: EX-10.23(C) Material Contract HTML 66K
19: EX-10.23(D) Material Contract HTML 101K
20: EX-10.24(A) Material Contract HTML 219K
21: EX-10.24(B) Material Contract HTML 77K
22: EX-10.24(C) Material Contract HTML 66K
23: EX-23.4 Consent of Expert or Counsel HTML 54K
24: EX-23.5 Consent of Expert or Counsel HTML 54K
25: EX-99.1 Miscellaneous Exhibit HTML 53K
27: EX-99.10 Miscellaneous Exhibit HTML 54K
28: EX-99.11 Miscellaneous Exhibit HTML 54K
29: EX-99.12 Miscellaneous Exhibit HTML 54K
30: EX-99.13 Miscellaneous Exhibit HTML 54K
26: EX-99.9 Miscellaneous Exhibit HTML 54K
37: R1 Document and Entity Information HTML 68K
38: R2 Condensed Consolidated Balance Sheets HTML 171K
39: R3 Condensed Consolidated Balance Sheets HTML 83K
(Parenthetical)
40: R4 Condensed Consolidated Statements of Operations HTML 134K
and Comprehensive Loss (Unaudited)
41: R5 Condensed Consolidated Statements of Operations HTML 56K
and Comprehensive Loss (Unaudited) (Parenthetical)
42: R6 Condensed Consolidated Statements of Shareholders' HTML 122K
Equity (Unaudited)
43: R7 Condensed Consolidated Statements of Cash Flows HTML 195K
(Unaudited)
44: R8 Condensed Balance Sheets (Brooklyn HTML 144K
ImmunoTherapeutics, LLC)
45: R9 Condensed Statements of Operations (Unaudited) HTML 103K
(Brooklyn ImmunoTherapeutics, LLC)
46: R10 Condensed Statements of Changes in Members' Equity HTML 149K
(Brooklyn ImmunoTherapeutics, LLC)
47: R11 Condensed Statements of Cash Flows (Brooklyn HTML 265K
ImmunoTherapeutics, LLC)
48: R12 Basis of Presentation HTML 62K
49: R13 Organization of Company HTML 61K
50: R14 Merger Agreement and Asset Purchase Agreement HTML 60K
51: R15 Covid-19-Update HTML 59K
52: R16 Going Concern Uncertainty HTML 66K
53: R17 Summary of Significant Accounting Policies And HTML 131K
Estimates
54: R18 Restricted Cash HTML 59K
55: R19 Fixed Assets, Net HTML 65K
56: R20 Fair Value of Financial Instruments HTML 62K
57: R21 Accrued Compensation HTML 61K
58: R22 Concentrations of Risk HTML 60K
59: R23 Revenue Recognition HTML 112K
60: R24 Basic and Diluted Earnings Per Common Share HTML 59K
61: R25 Shareholders' Equity HTML 116K
62: R26 Income Taxes HTML 87K
63: R27 Debt HTML 66K
64: R28 Long-term Debt HTML 59K
65: R29 Leases HTML 110K
66: R30 Commitments and Contingencies HTML 58K
67: R31 Disposition of Site Equipment to Be Installed and HTML 61K
Fixed Assets
68: R32 Software Development Costs HTML 60K
69: R33 Goodwill HTML 66K
70: R34 Accumulated Other Comprehensive Income HTML 59K
71: R35 Recent Accounting Pronouncements HTML 65K
72: R36 Retirement Savings Plan HTML 57K
73: R37 Subsequent Events HTML 65K
74: R38 Organization and Description of Business HTML 65K
Operations (Brooklyn ImmunoTherapeutics, LLC)
75: R39 Description of Business (Brooklyn HTML 57K
ImmunoTherapeutics, LLC) (10-K)
76: R40 Going Concern (Brooklyn ImmunoTherapeutics, LLC) HTML 72K
77: R41 Basis of Presentation and Summary of Significant HTML 72K
Accounting Policies (Brooklyn ImmunoTherapeutics,
LLC)
78: R42 Summary of Significant Accounting Policies HTML 150K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
79: R43 Merger With NTN Buzztime, Inc (Brooklyn HTML 59K
ImmunoTherapeutics, LLC)
80: R44 Fair Value of Financial Instruments (Brooklyn HTML 74K
ImmunoTherapeutics, LLC)
81: R45 Business Combination (Brooklyn ImmunoTherapeutics, HTML 61K
LLC) (10-K)
82: R46 Property and Equipment (Brooklyn HTML 76K
ImmunoTherapeutics, LLC)
83: R47 Goodwill and in Process Research and Development HTML 56K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
84: R48 Security Deposits and Other Assets (Brooklyn HTML 58K
ImmunoTherapeutics, LLC)
85: R49 Accrued Expenses (Brooklyn ImmunoTherapeutics, HTML 65K
LLC)
86: R50 Investor Deposits (Brooklyn ImmunoTherapeutics, HTML 55K
LLC) (10-K)
87: R51 Loans Payable (Brooklyn ImmunoTherapeutics, LLC) HTML 68K
88: R52 Loans Payable and Loans Payable to Related Parties HTML 59K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
89: R53 Commitments and Contingencies (Brooklyn HTML 82K
ImmunoTherapeutics, LLC)
90: R54 Stock-Based Compensation (Brooklyn HTML 62K
ImmunoTherapeutics, LLC)
91: R55 Members' Equity (Brooklyn ImmunoTherapeutics, LLC) HTML 57K
92: R56 Stockholders' Deficiency and Members' Equity HTML 75K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
93: R57 Income Tax (Brooklyn ImmunoTherapeutics, LLC) HTML 101K
(10-K)
94: R58 Subsequent Events (Brooklyn ImmunoTherapeutics, HTML 72K
LLC)
95: R59 Summary of Significant Accounting Policies And HTML 180K
Estimates (Policies)
96: R60 Basis of Presentation and Summary of Significant HTML 96K
Accounting Policies (Policies) (Brooklyn
ImmunoTherapeutics, LLC)
97: R61 Summary of Significant Accounting Policies HTML 129K
(Policies) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
98: R62 Summary of Significant Accounting Policies And HTML 118K
Estimates (Tables)
99: R63 Fixed Assets, Net (Tables) HTML 66K
100: R64 Accrued Compensation (Tables) HTML 59K
101: R65 Revenue Recognition (Tables) HTML 118K
102: R66 Shareholders' Equity (Tables) HTML 100K
103: R67 Income Taxes (Tables) HTML 84K
104: R68 Leases (Tables) HTML 95K
105: R69 Goodwill (Tables) HTML 63K
106: R70 Business Combination (Tables) (Brooklyn HTML 60K
ImmunoTherapeutics, LLC) (10-K)
107: R71 Fair Value of Financial Instruments (Tables) HTML 63K
(Brooklyn ImmunoTherapeutics, LLC)
108: R72 Property and Equipment (Tables) (Brooklyn HTML 70K
ImmunoTherapeutics, LLC)
109: R73 Accrued Expenses (Tables) (Brooklyn HTML 64K
ImmunoTherapeutics, LLC)
110: R74 Commitments and Contingencies (Tables) (Brooklyn HTML 59K
ImmunoTherapeutics, LLC) (10-K)
111: R75 Stockholders' Deficiency and Members' Equity HTML 83K
(Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)
112: R76 Income Tax (Tables) (Brooklyn ImmunoTherapeutics, HTML 89K
LLC) (10-K)
113: R77 Basis of Presentation (Details Narrative) HTML 55K
114: R78 Organization of Company (Details Narrative) (10-K) HTML 61K
115: R79 Merger Agreement and Asset Purchase Agreement HTML 74K
(Details Narrative)
116: R80 Covid-19-Update (Details Narrative) HTML 60K
117: R81 Going Concern Uncertainty (Details Narrative) HTML 97K
118: R82 Going Concern Uncertainty (Details Narrative) HTML 78K
(10-K)
119: R83 Summary of Significant Accounting Policies and HTML 199K
Estimates (Details Narrative) (10-K)
120: R84 Summary of Significant Accounting Policies and HTML 78K
Estimates - Schedule of Disaggregation of Revenues
(Details) (10-K)
121: R85 Summary of Significant Accounting Policies and HTML 61K
Estimates - Schedule of Revenues Geographic
Breakdown (Details) (10-K)
122: R86 Summary of Significant Accounting Policies and HTML 65K
Estimates - Schedule of Contract Liabilities
(Details) (10-K)
123: R87 Summary of Significant Accounting Policies and HTML 63K
Estimates - Schedule of Unamortized Installation
Cost and Sales Commissions (Details) (10-K)
124: R88 Restricted Cash (Details Narrative) HTML 72K
125: R89 Restricted Cash (Details Narrative) (10-K) HTML 75K
126: R90 Fixed Assets, Net (Details Narrative) (10-K) HTML 56K
127: R91 Fixed Assets, Net - Schedule of Property and HTML 70K
Equipment (Details) (10-K)
128: R92 Fixed Assets, Net - Schedule of Asset Geographic HTML 59K
Breakdown (Details) (10-K)
129: R93 Accrued Compensation - Schedule of Accrued HTML 66K
Compensation (Details) (10-K)
130: R94 Concentrations of Risk (Details Narrative) (10-K) HTML 75K
131: R95 Revenue Recognition - (Details Narrative) HTML 62K
132: R96 Revenue Recognition - Schedule of Disaggregates HTML 78K
Material Revenue (Details)
133: R97 Revenue Recognition - Schedule of Revenues HTML 62K
Geographic Breakdown (Details)
134: R98 Revenue Recognition - Schedule of Contract HTML 66K
Liabilities (Details)
135: R99 Revenue Recognition - Schedule of Unamortized HTML 64K
Installation Cost and Sales Commissions (Details)
136: R100 Basic and Diluted Earnings Per Common Share HTML 57K
(Details Narrative)
137: R101 Basic and Diluted Earnings Per Common Share HTML 57K
(Details Narrative) (10-K)
138: R102 Shareholders' Equity (Details Narrative) HTML 102K
139: R103 Shareholders' Equity (Details Narrative) (10-K) HTML 171K
140: R104 Shareholders' Equity - Schedule of Weighted HTML 64K
Average Assumptions (Details)
141: R105 Shareholders' Equity - Schedule of Weighted HTML 64K
Average Assumptions (Details) (10-K)
142: R106 Shareholders' Equity - Schedule of Restricted HTML 58K
Stock and Common Stock Unit Vested (Details)
143: R107 Shareholders' Equity - Summary of Stock Option HTML 104K
Activity (Details) (10-K)
144: R108 Shareholders' Equity - Summary of Restricted Stock HTML 76K
Unit Activity (Details) (10-K)
145: R109 Shareholders' Equity - Summary of Warrant HTML 77K
Activities (Details) (10-K)
146: R110 Income Taxes (Details Narrative) (10-K) HTML 71K
147: R111 Income Taxes - Schedule of Current and Deferred HTML 89K
Income Tax Provision (Benefit) (Details) (10-K)
148: R112 Income Taxes - Schedule of Deferred Tax Assets and HTML 95K
Liabilities (Details) (10-K)
149: R113 Income Taxes - Schedule of Reconciliation of HTML 72K
Expected Income Taxes (Details) (10-K)
150: R114 Debt (Details Narrative) HTML 159K
151: R115 Long-term Debt (Details Narrative) (10-K) HTML 88K
152: R116 Leases (Details Narrative) HTML 122K
153: R117 Leases (Details Narrative) (10-K) HTML 78K
154: R118 Leases - Schedule of Operating Lease Right-of-use HTML 79K
Assets and Liabilities (Details)
155: R119 Leases - Schedule of Operating Lease Right-of-use HTML 74K
Assets and Liabilities (Details) (10-K)
156: R120 Leases - Schedule of Maturities of Operating HTML 74K
Leases (Details) (10-K)
157: R121 Leases - Schedule of Financing Lease Right-of-use HTML 67K
Assets and Liabilities (Details)
158: R122 Leases - Schedule of Financing Lease Right-of-use HTML 66K
Assets and Liabilities (Details) (10-K)
159: R123 Leases - Schedule of Maturities of Financing HTML 64K
Leases (Details)
160: R124 Leases - Schedule of Maturities of Financing HTML 65K
Leases (Details) (10-K)
161: R125 Disposition of Site Equipment to Be Installed and HTML 70K
Fixed Assets (Details Narrative)
162: R126 Software Development Costs (Details Narrative) HTML 62K
163: R127 Goodwill (Details Narrative) HTML 60K
164: R128 Goodwill (Details Narrative) (10-K) HTML 60K
165: R129 Goodwill - Schedule of Goodwill (Details) HTML 63K
166: R130 Goodwill - Schedule of Goodwill (Details) (10-K) HTML 64K
167: R131 Accumulated Other Comprehensive Income (Details HTML 57K
Narrative)
168: R132 Accumulated Other Comprehensive Income (Details HTML 57K
Narrative) (10-K)
169: R133 Retirement Savings Plan (Details Narrative) (10-K) HTML 57K
170: R134 Subsequent Events (Details Narrative) HTML 63K
171: R135 Subsequent Events (Details Narrative) (10-K) HTML 121K
172: R136 Going Conern (Details Narrative) (Brooklyn HTML 68K
ImmunoTherapeutics, LLC)
173: R137 Basis of Presentation and Summary of Significant HTML 62K
Accounting Policies (Details Narrative) (Brooklyn
ImmunoTherapeutics, LLC)
174: R138 Merger With NTN Buzztime, Inc (Details Narrative) HTML 68K
(Brooklyn ImmunoTherapeutics, LLC)
175: R139 Fair Value of Financial Instruments (Details HTML 61K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
176: R140 Fair Value of Financial Instruments - Schedule of HTML 64K
Fair Value of Liabilities (Details) (Brooklyn
ImmunoTherapeutics, LLC)
177: R141 Property and Equipment (Details Narrative) HTML 56K
(Brooklyn ImmunoTherapeutics, LLC)
178: R142 Property and Equipment - Schedule of Property and HTML 68K
Equipment (Details) (Brooklyn ImmunoTherapeutics,
LLC)
179: R143 Security Deposits and Other Assets (Details HTML 62K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
180: R144 Accrued Expenses (Details) (Brooklyn HTML 67K
ImmunoTherapeutics, LLC)
181: R145 Loans Payable (Details Narrative) (Brooklyn HTML 59K
ImmunoTherapeutics, LLC)
182: R146 Commitments and Contingencies (Details Narrative) HTML 99K
(Brooklyn ImmunoTherapeutics, LLC)
183: R147 Stock-Based Compensation (Details Narrative) HTML 56K
(Brooklyn ImmunoTherapeutics, LLC)
184: R148 Members' Equity (Details Narrative) (Brooklyn HTML 67K
ImmunoTherapeutics, LLC)
185: R149 Going Conern (Details Narrative) (Brooklyn HTML 86K
ImmunoTherapeutics, LLC) (10-K)
186: R150 Summary of Significant Accounting Policies HTML 72K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
187: R151 Business Combination (Details Narrative) (Brooklyn HTML 63K
ImmunoTherapeutics, LLC) (10-K)
188: R152 Business Combination - Schedule of Purchase Price HTML 83K
for Acquisition (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
189: R153 Property and Equipment (Details Narative) HTML 63K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
190: R154 Property and Equipment - Schedule of Property and HTML 68K
Equipment (Details) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
191: R155 Goodwill and in Process Research and Development HTML 59K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
192: R156 Security Deposits and Other Assets (Details HTML 65K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
193: R157 Accrued Expenses (Details) (Brooklyn HTML 70K
ImmunoTherapeutics, LLC) (10K)
194: R158 Investor Deposits (Details Narrative) (Brooklyn HTML 55K
ImmunoTherapeutics, LLC) (10-K)
195: R159 Loans Payable and Loans Payable to Related Parties HTML 101K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
196: R160 Commitments and Contingencies (Details Narrative) HTML 130K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
197: R161 Commitments and Contingencies - Schedule of Future HTML 72K
Commitments of Operating Lease (Details) (Brooklyn
ImmunoTherapeutics, LLC)
198: R162 Stockholders' Deficiency and Members' Equity HTML 167K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
199: R163 Stockholders' Deficiency and Members' Equity - HTML 92K
Schedule of Stock Option Activity (Details)
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
200: R164 Stockholders' Deficiency and Members' Equity - HTML 70K
Schedule of Stock Options Outstanding and
Exercisable (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
201: R165 Income Tax (Details Narrative) (Brooklyn HTML 61K
ImmunoTherapeutics, LLC) (10-K)
202: R166 Income Tax - Schedule of Income Tax Benefit HTML 84K
(Details) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
203: R167 Income Tax - Schedule of Deferred Tax Assets and HTML 61K
Liabilities (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
204: R168 Subsequent Events (Details Narrative) (Brooklyn HTML 61K
ImmunoTherapeutics, LLC) (10-K)
206: XML IDEA XML File -- Filing Summary XML 371K
205: EXCEL IDEA Workbook of Financial Reports XLSX 284K
31: EX-101.INS XBRL Instance -- ntn-20200930 XML 3.47M
33: EX-101.CAL XBRL Calculations -- ntn-20200930_cal XML 459K
34: EX-101.DEF XBRL Definitions -- ntn-20200930_def XML 2.03M
35: EX-101.LAB XBRL Labels -- ntn-20200930_lab XML 2.11M
36: EX-101.PRE XBRL Presentations -- ntn-20200930_pre XML 2.34M
32: EX-101.SCH XBRL Schema -- ntn-20200930 XSD 461K
207: ZIP XBRL Zipped Folder -- 0001493152-20-022484-xbrl Zip 337K
Exhibit 99.1
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/01/22 Eterna Therapeutics Inc. 10-K/A 12/31/21 92:11M Broadridge Fin’l So… Inc 4/15/22 Eterna Therapeutics Inc. 10-K 12/31/21 95:10M Broadridge Fin’l So… Inc 11/23/21 Eterna Therapeutics Inc. S-1/A 2:185K Broadridge Fin’l So… Inc 11/18/21 Eterna Therapeutics Inc. S-1 4:602K Broadridge Fin’l So… Inc 5/27/21 Eterna Therapeutics Inc. S-1 4:660K Broadridge Fin’l So… Inc 4/30/21 Eterna Therapeutics Inc. S-1 8:2.2M Broadridge Fin’l So… Inc 1/20/21 Eterna Therapeutics Inc. S-4/A 1/19/21 182:20M M2 Compliance LLC/FA 12/22/20 Eterna Therapeutics Inc. S-4/A 183:20M M2 Compliance LLC/FA |